BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Biotech catalysts in 2024-01

169 industry Phase 2/3 trial readout(s) and 23 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.

← 2023-12 | 2024-02 →

FDA decision events

DateEventStatusCompanyDrugSource
2024-01-04Complete response letterapproved sinceAstellas Pharma US, Inc.IMAB362CRL 2024-01-04: Astellas Pharma US, Inc. BLA 761365 (IMAB362)
2024-01-05FDA approvalapprovedLNHCZELSUVMIApproved 2024-01-05: ZELSUVMI (NDA217424 ORIG1)
2024-01-05FDA approvalapprovedFRESENIUS KABI USAIDACIOApproved 2024-01-05: IDACIO (BLA761255 ORIG2)
2024-01-08FDA approvalapprovedPROVEPHARM SASPROVAYBLUEApproved 2024-01-08: PROVAYBLUE (NDA204630 SUPPL21)
2024-01-12Complete response lettercomplete responseSQ Innovation, Inc.furosemide injectionCRL 2024-01-12: SQ Innovation, Inc. NDA 217294 (furosemide injection)
2024-01-12FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2024-01-12: KEYTRUDA (BLA125514 SUPPL147)
2024-01-12FDA approvalapprovedREGENERON PHARMACEUTICALS REGNDUPIXENTApproved 2024-01-12: DUPIXENT (BLA761055 SUPPL55)
2024-01-17Complete response lettercomplete responseBendaRx USA Corporationone or more listed drugs (LDs) for approval, you must establish that such reliance is scientifically appropriateCRL 2024-01-17: BendaRx USA Corporation NDA 215291 (one or more listed drugs (LDs) for approval, you must establish that such reliance is scientifically appropriate)
2024-01-18FDA approvalapprovedNOVARTIS NVSPIQRAYApproved 2024-01-18: PIQRAY (NDA212526 SUPPL9)
2024-01-19Complete response letterapproved sinceAkeso Biopharma Co., Ltd.CRL 2024-01-19: Akeso Biopharma Co., Ltd. BLA 761258
2024-01-19FDA approvalapprovedJANSSEN BIOTECHBALVERSAApproved 2024-01-19: BALVERSA (NDA212018 SUPPL8)
2024-01-19FDA approvalapprovedJANSSEN BIOTECHBALVERSAApproved 2024-01-19: BALVERSA (NDA212018 SUPPL9)
2024-01-23Complete response lettercomplete responseHikma Pharmaceuticals USA, Inc.phenobarbital sodium injectionCRL 2024-01-23: Hikma Pharmaceuticals USA, Inc. NDA 218258 (phenobarbital sodium injection)
2024-01-23FDA approvalapprovedHERON THERAPS INCZYNRELEF KITApproved 2024-01-23: ZYNRELEF KIT (NDA211988 SUPPL13)
2024-01-24FDA approvalapprovedASTRAZENECA AZNKOSELUGOApproved 2024-01-24: KOSELUGO (NDA213756 SUPPL4)
2024-01-25Complete response lettercomplete responseDefender Pharmaceuticals, IncCRL 2024-01-25: Defender Pharmaceuticals, Inc NDA 214315
2024-01-25Complete response lettercomplete responseAFT Pharmaceuticals LtdsirolimusCRL 2024-01-25: AFT Pharmaceuticals Ltd NDA 218528 (sirolimus cream)
2024-01-25FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2024-01-25: KEYTRUDA (BLA125514 SUPPL124)
2024-01-25FDA approvalapprovedREGENERON PHARMACEUTICALS REGNDUPIXENTApproved 2024-01-25: DUPIXENT (BLA761055 SUPPL57)
2024-01-26FDA approvalapprovedBRISTOL MYERS SQUIBB BMYOPDIVOApproved 2024-01-26: OPDIVO (BLA125554 SUPPL122)
2024-01-26FDA approvalapprovedABBVIE ABBVAVYCAZApproved 2024-01-26: AVYCAZ (NDA206494 SUPPL12)
2024-01-30Complete response lettercomplete responseAccord Healthcare Inc.EpinephrineCRL 2024-01-30: Accord Healthcare Inc. NDA 218470 (Epinephrine injection)
2024-01-31FDA approvalapprovedASTRAZENECA AZNTAGRISSOApproved 2024-01-31: TAGRISSO (NDA208065 SUPPL29)

Trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2024-01 est.P3Mentor Worldwide, LLCNCT00981266 Spectra Breast Implant StudyAugmentation; Augmentation Revision; General Breast Enlargement; Post-lactational Involution; Asymmewithdrawn
2024-01 est.P1/P2Conjupro Biotherapeutics, Inc.NCT03553914 PLM60 for Peripheral T Cell Lymphoma (PTCL)Peripheral T Cell Lymphomawithdrawn
2024-01 est.P2Sorrento Therapeutics, Inc.NCT03999658 A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory MalignanciesPeripheral T Cell Lymphoma; Diffuse Large B Cell Lymphoma; Biliary Tract Cancer; Extranodal NK T Celwithdrawn
2024-01 est.P1/P2Ascentage Pharma Group Inc. AAPGNCT04674514 APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple MyelomaMultiple Myelomaunknown48
2024-01 est.P2Frame Pharmaceuticals B.V.NCT04998474 FRAME-001 Personalized Vaccine in NSCLCNon Small Cell Lung Cancerunknown15
2024-01 est.P2/P3Alachua Government Services, Inc.NCT05142527 Study to Evaluate the Safety and Efficacy of a Monoclonal Antibody Cocktail for the Prevention of COVID-19COVID-19withdrawn
2024-01 est.P2Saol Therapeutics IncNCT05470608 Phase II Study to Assess Safety and Efficacy of SL-1002 for Osteoarthritic Knee PainOsteoarthritis, Knee Painunknown132
2024-01 est.P2Soleno Therapeutics, Inc.NCT05532020 An Open-Label Study of Diazoxide Choline in Patients With Genetic ObesitiesSH2B1 Deficiency Obesity; Obesity Associated With PCSK1 Mutation (rs6232 Variant); SIM1 Deficiency Owithdrawn
2024-01 est.P2Telios Pharma, Inc.NCT06153342 A Study of TL-925 for the Treatment of Allergic ConjunctivitisAllergic Conjunctivitisunknown70
2024-01-01P3AbbVie ABBVNCT02814916 Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive OrMethicillin-Resistant Staphylococcus Aureus; Bacterial Infections; Staphylococcal Skin Infectionscompleted199
2024-01-01 est.P2Qilu Pharmaceutical Co., Ltd.NCT05329025 A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung CancerNon-small-cell Lung Cancerunknown100
2024-01-01 est.P2Mabwell (Shanghai) Bioscience Co., Ltd.NCT05440045 A Clinical Study of 6MW3211 in Patients With Renal CancerAdvanced Clear Cell Renal Cell Carcinomaunknown30
2024-01-01P2Pfizer PFENCT05886777 A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial ViHealthy Participantscompleted1142
2024-01-01 est.P1/P2Aptevo Therapeutics APVONCT05934539 ALG.APV-527 First-in-human StudySolid Tumorunknown56
2024-01-02P2/P3Eli Lilly and Company LLYNCT03706365 A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate CancerProstate Canceractive not recruiting393
2024-01-02P3VectivBio AGNCT04627025 Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IFShort Bowel Syndromecompleted164
2024-01-02P2CSL BehringNCT05130970 Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosiscompleted81
2024-01-02P2Chipscreen Biosciences, Ltd.NCT05193916 A Phase II Clinical Trial of Chiglitazar for NASHNASHcompleted104
2024-01-02P2Ventyx Biosciences, IncNCT05715125 VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)Psoriatic Arthritisterminated205
2024-01-03P3AstraZeneca AZNNCT04075292 Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic LeukemiaUntreated Chronic Lymphocytic Leukemiaactive not recruiting155
2024-01-03P2AbbVie ABBVNCT04451772 A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With ModeratelSystemic Lupus Erythematosus (SLE)completed185
2024-01-03P3Takeda TAKNCT04974749 A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry DiseaseFabry Diseasecompleted20
2024-01-03P2Seagen Inc.NCT04993677 A Study of SEA-CD40 Given With Other Drugs in CancersMelanoma; Carcinoma, Non-Small- Cell Lungcompleted77
2024-01-03P3Janssen Research & Development, LLCNCT05388669 A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated AAdvanced or Metastatic Non-small Cell Lung Canceractive not recruiting418
2024-01-03P2BayerNCT05656911 A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-seveAtopic Dermatitiscompleted77
2024-01-04P2/P3Merck Sharp & Dohme LLC MRKNCT04732221 A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sPulmonary Arterial Hypertension; Hypertension, Pulmonarycompleted168
2024-01-04P2/P3Galderma R&DNCT05075408 To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe PruritusChronic Kidney Disease Associated Moderate to Severe Prurituscompleted258
2024-01-04P3BayerNCT05147662 A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Treatment of Bleeding; Prophylaxis of Bleeding; Hemophilia A; Childrencompleted36
2024-01-04P2Amgen AMGNNCT05540665 Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)Lupus Nephritisterminated19
2024-01-04P2GEN İlaç ve Sağlık Ürünleri A.Ş.NCT05706870 Phase II Study Evaluating the Clinical Efficacy and Safety of GN-037 in Plaque PsoriasisPsoriasiscompleted190
2024-01-04P3Faes Farma, S.A.NCT05788497 Efficacy and Safety of Hemorrane Plus Versus Hemorrane and Versus Placebo in Patients With Uncomplicated HaemorrhoidsHaemorrhoids Without Complicationterminated21
2024-01-04P2Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06118008 A Study of HS-20094 in T2DM ParticipantsType 2 Diabetescompleted54
2024-01-04P3Taejoon Pharmaceutical Co., Ltd.NCT06287606 A Phase 3 Clinical Trials for Bowel Preparation for ColonoscopyBowel Preparationcompleted161
2024-01-05P1/P2Bristol-Myers Squibb BMYNCT03195478 A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid TumorsSolid Tumorcompleted37
2024-01-05P3AstraZeneca AZNNCT03521154 A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)Non Small Cell Lung Cancer (Stage III)active not recruiting216
2024-01-05P2Pfizer PFENCT04440176 A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 SchedulesMeningococcal Vaccinecompleted309
2024-01-05P1/P2Eirion Therapeutics Inc.NCT05565950 AI-09 In Subjects With Glabellar Lines, GL-101Glabellar Frown Linescompleted96
2024-01-05P3ModernaTX, Inc.NCT05566639 A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and OlderSeasonal Influenzacompleted22502
2024-01-05P3Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.NCT05642078 Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split VaccinePrevention of Influenzacompleted2550
2024-01-05P3AO GENERIUMNCT06475508 Comparison of Complarate® (Tocilizumab Biosimilar) and Actemra® in Patients With Rheumatoid ArthritisRheumatoid Arthritiscompleted465
2024-01-06P2Bristol-Myers Squibb BMYNCT05556265 A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia AreataAlopecia Areataterminated94
2024-01-07P3ShionogiNCT05305547 A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19SARS-CoV-2 Infectioncompleted2093
2024-01-08P1/P2Handok Inc.NCT04492033 A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor PatientsP1b: Advanced Solid Tumors; P2: Biliary Tract Cancerterminated41
2024-01-08 est.P2Takeda TAKNCT04985656 A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic SyndromesMyelodysplastic Syndromes (MDS)withdrawn
2024-01-08P1/P2T-knife GmbHNCT05430555 A Phase 1/ 2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/ MeAdvanced Solid Tumorsterminated23
2024-01-09P2Medipost Co Ltd.NCT03392467 PNEUMOSTEM for the Prevention and Treatment of Severe BPD in Premature InfantsSevere Bronchopulmonary Dysplasiacompleted60
2024-01-09P3Novo Nordisk A/S NVONCT03819153 A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney DiseaseDiabetes Mellitus, Type 2completed3533
2024-01-09P1/P2Orion Corporation, Orion Pharma ORNNCT03878823 Safety and Pharmacokinetics of ODM-209Prostate Cancer Metastatic; Advanced Breast Cancer; Castration-resistant Prostate Cancer; Metastaticcompleted38
2024-01-09P1/P2Beijing Mabworks Biotech Co., Ltd.NCT04110301 MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)Follicular Lymphoma and Marginal Zone Lymphomaunknown53
2024-01-09P2Beijing InnoCare Pharma Tech Co., Ltd.NCT04440059 A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom MacroglobulinemiaWaldenstrom's Macroglobulinemia Recurrent; Waldenstrom's Macroglobulinemia Refractorycompleted47
2024-01-09P3Veru Inc. VERUNCT04869943 Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast CancerMetastatic Breast Cancerterminated52
2024-01-09P2/P3Hipra Scientific, S.L.UNCT05303402 A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults.SARS CoV 2 Infectioncompleted240
2024-01-09P2Alexion Pharmaceuticals, Inc.NCT05565092 Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell DiseaseSickle Cell Disease (SCD)terminated2
2024-01-09P2Kiora Pharmaceuticals, Inc. KPRXNCT05629364 A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment Dry Eye Diseaseterminated4
2024-01-09P3Ferrer Internacional S.A.NCT05866926 Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosisterminated201
2024-01-10P3Techfields Pharma Co. LtdNCT03081806 A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis Knee PainPain Associated With Osteoarthritis of the Kneecompleted399
2024-01-10P1/P2Ability Pharmaceuticals SLNCT04431258 ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic StudyPancreatic Cancercompleted150
2024-01-10P2Boehringer IngelheimNCT04521478 A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With DepressionDepressive Disorder, Majorcompleted389
2024-01-10P2Annexon, Inc. ANNXNCT04569435 Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosiscompleted17
2024-01-10P2Ionis Pharmaceuticals, Inc. IONSNCT04932512 A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224Steatohepatitis, Nonalcoholiccompleted160
2024-01-10P2Neurocrine Biosciences NBIXNCT05203341 Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)Major Depressive Disordercompleted183
2024-01-10P3Chong Kun Dang PharmaceuticalNCT05566028 The Efficacy and Safety of D745 Added to D150 Plus D759 Therapy in Patients with Type 2 DiabetesType 2 Diabetescompleted172
2024-01-11P2Ultimovacs ASANCT04382664 UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of MelanomaMalignant Melanomacompleted156
2024-01-11P2Bristol-Myers Squibb BMYNCT04623775 A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants WiNon-small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Metastatic Non-small Cell Lung Cancompleted468
2024-01-11P3CelgeneNCT04753697 A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic EsophagitisEosinophilic Esophagitiscompleted430
2024-01-11 est.P3Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdNCT05156528 Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 YearsDysentery; Shigellosisunknown21000
2024-01-11P3Eli Lilly and Company LLYNCT05369403 A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With DupilumabAtopic Dermatitiscompleted86
2024-01-11P2Silence Therapeutics plc SLNNCT05537571 Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease EventsCardiovascular Diseases; Atherosclerosis; Lipoprotein(a)completed180
2024-01-12P3Omeros Corporation OMERNCT03608033 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) NephropathyIgA Nephropathyterminated360
2024-01-12P1/P2Menarini GroupNCT04495621 MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)Metastatic Colorectal Cancercompleted29
2024-01-12P2Enlivex Therapeutics Ltd. ENLVNCT04612413 A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult SepsisSepsis; Community-acquired Pneumonia; Urinary Tract Infections; Cholecystitis, Acute; Cholangitis Accompleted148
2024-01-12P2Hangzhou Hanx Biopharmaceuticals, Ltd.NCT04886271 Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid TumorsAdvanced Solid Tumorcompleted20
2024-01-12P3Organon and Co OGNNCT05264506 Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral ContraceptiveContraceptionterminated3055
2024-01-12P2Suzhou Raymon Pharmaceuticals Company, Ltd.NCT05794204 RMP-A03 Ocular Suspension in Patients With PterygiumPterygiumcompleted77
2024-01-15P3AstraZeneca AZNNCT03703297 Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent CheSmall Cell Lung Canceractive not recruiting730
2024-01-15P2/P3MacroGenics MGNXNCT04082364 Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerGastric Cancer; Gastroesophageal Junction Cancer; HER2-positive Gastric Cancercompleted82
2024-01-15P2Novartis Pharmaceuticals NVSNCT04129528 Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult SubjectsType 1 Diabetes Mellituscompleted44
2024-01-15P2Allay Therapeutics, Inc.NCT05260008 Study Assessing Pain Relief After Replacement of the KneeAcute Postoperative Painterminated112
2024-01-15P3EuBiologics Co.,LtdNCT05603052 A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and OlderCOVID-19completed2852
2024-01-15P2Sinocelltech Ltd.NCT05652543 A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 VaccineCOVID-19 Pandemiccompleted518
2024-01-15P3Medprin Regenerative Medical Technologies Co., Ltd.NCT07764055 A Trial of Absorbable Regenerated Oxidized Cellulose for Surgical Hemostasis)Surgical Bleeding; Hemorrhage; Oxidized Regenerated Cellulosecompleted288
2024-01-16P3ActelionNCT03232073 Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple SclerosisMultiple Sclerosiscompleted877
2024-01-16P1/P2Barinthus BiotherapeuticsNCT04607850 Prime-boost Vaccine Study in Women With Low-grade Cervical HPV LesionsHPV Infection; CIN1completed108
2024-01-16P1/P2atai Therapeutics, Inc.NCT05029401 A Study of Oral Ibogaine in Opioid WithdrawalOpiate Withdrawal Syndromecompleted116
2024-01-16P3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05375461 TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical TrailHR-positive,HER2-negative in Advanced Breast Cancercompleted293
2024-01-16P2/P3Novavax NVAXNCT05468736 Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 YearsCOVID-19completed3600
2024-01-16P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05987371 A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.Chronic Obstructive Pulmonary Diseasecompleted75
2024-01-17P2Tanabe Pharma America, Inc.NCT04440592 Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic SclerosisDiffuse Cutaneous Systemic Sclerosiscompleted76
2024-01-17P2Supernus Pharmaceuticals, Inc. SUPNNCT05318937 A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive ImpairmentParkinson Disease; Cognitive Dysfunctioncompleted86
2024-01-17P3Sobi, Inc.NCT05369208 Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITPImmune Thrombocytopeniacompleted19
2024-01-17P2Suzhou Alphamab Co., Ltd.NCT05421429 KN057 Multiple Dose Study in Moderately Severe to Severe HemophiliaHemophiliacompleted24
2024-01-17P2/P3Neurocentria, Inc.NCT05683249 Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)ADHDcompleted223
2024-01-18P3Pfizer PFENCT04218084 Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell DiseaseSickle Cell Diseaseterminated236
2024-01-18P3Biogen BIIBNCT05265728 A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Multiple Sclerosis, Relapsing-Remittingterminated21
2024-01-18P3Pfizer PFENCT05399485 Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)Migrainecompleted496
2024-01-18P2Mylan Pharmaceuticals IncNCT06048536 Dose-finding Study of MR-130A-01 Contraceptive Transdermal PatchContraceptioncompleted168
2024-01-19P1/P2BioNTech SE BNTXNCT04101357 Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411Solid Tumor; Extensive-stage Small Cell Lung Cancerterminated54
2024-01-19P2Regeneron Pharmaceuticals REGNNCT04633278 CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaSquamous Cell Carcinoma of Head and Neckterminated24
2024-01-19P3Amylyx Pharmaceuticals Inc. AMLXNCT05021536 Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis TreatmentAmyotrophic Lateral Sclerosisunknown664
2024-01-19P2Microbion CorporationNCT05174806 Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI PatientsDiabetic Foot Infection; Diabetic Footcompleted47
2024-01-19P3Pfizer PFENCT05399459 Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)Migrainecompleted897
2024-01-19P1/P2Sanofi Pasteur, a Sanofi Company SNYNCT05553301 Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and OlderInfluenza Immunizationcompleted560
2024-01-19P2/P3HilleVaxNCT05836012 Safety and Immunogenicity of HIL-214 With Routine Pediatric VaccinesGastroenteritiscompleted329
2024-01-19P2Changchun GeneScience Pharmaceutical Co., Ltd.NCT05936281 A Study of the Efficacy of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering (GenSci048-202)Gout; Gout Initiating Urate-loweringUrate-lowering Therapycompleted165
2024-01-20P3Crinetics Pharmaceuticals Inc.NCT05192382 A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)Acromegalyterminated111
2024-01-20 est.P2Shanghai Kechow Pharma, Inc.NCT05233332 Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)CRCunknown186
2024-01-21P2Shanghai Ming Ju Biotechnology Co., Ltd.NCT06093841 Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHLLymphoma, Large B-Cell, Diffuse; Follicular Lymphoma Grade 3B; High-grade B-cell Lymphoma; Mediastinactive not recruiting46
2024-01-22P2Provention Bio, a Sanofi CompanyNCT04270942 At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)Diabetes Mellitus, Type 1completed6
2024-01-22P3Arcutis Biotherapeutics, Inc. ARQTNCT04286607 Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque PsoriasisChronic Plaque Psoriasiscompleted337
2024-01-22P3China National Biotec Group Company LimitedNCT05091619 A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, AdsorbedWhooping Cough; Diphtheria; Tetanusactive not recruiting2898
2024-01-22P2ADC Therapeutics S.A. ADCTNCT05144009 A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)Diffuse Large B-cell Lymphomaterminated41
2024-01-22P3AstraZeneca AZNNCT05171816 Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)Metastatic Castration-resistant Prostate Canceractive not recruiting110
2024-01-22P2QOL Medical, LLCNCT05703009 Effects of Sacrosidase and Placebo in Subjects With Fructan IntoleranceFructan Intolerancecompleted25
2024-01-23P2Pfizer PFENCT04321031 Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)Nonalcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis With Liver Fibrosiscompleted256
2024-01-23P1/P2BioNTech SE BNTXNCT04382898 PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)Prostate Cancerterminated75
2024-01-23P2Gilead Sciences GILDNCT04891770 Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)Chronic Hepatitis Bcompleted103
2024-01-23P2TiumBio Co., Ltd.NCT05138562 TUC3PII-01_TU2670 Phase IIa Clinical StudyEndometriosiscompleted86
2024-01-23P2EnteromeNCT05350501 EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal CancerColorectal Cancerterminated1
2024-01-23P2Medesis Pharma SANCT05423522 Clinical Safety and Efficacy Evaluation of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's DiseaseAlzheimer's Diseasecompleted72
2024-01-23P2UNION therapeutics UNPNCT05469464 Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)Atopic Dermatitis; Skin Diseasescompleted235
2024-01-24P2Ocular Therapeutix, Inc. OCULNCT05335122 A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHTOpen Angle Glaucoma; Ocular Hypertensioncompleted83
2024-01-24P2Ganzhou Hemay Pharmaceutical Co., LtdNCT05769946 A Study of Hemay005 in Adult With Atopic DermatitisHemay005, Atopic Dermatitiscompleted79
2024-01-24 est.P1/P2Immix Biopharma, Inc. IMMXNCT05840835 Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid TumorsAdvanced Solid Tumorunknown60
2024-01-25P1/P2Bristol-Myers Squibb BMYNCT02913313 A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid TumorsBroad Solid Tumorcompleted101
2024-01-25P3Amgen AMGNNCT03362177 Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal CancerChemotherapy-induced Thrombocytopeniacompleted165
2024-01-25P3BioTissue Holdings, IncNCT04176120 Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)Diabetic Foot Infection; Non-healing Wound; Non-healing Diabetic Foot Ulcercompleted220
2024-01-25P2BioNTech SE BNTXNCT04526899 A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to OthMelanoma Stage III; Melanoma Stage IV; Unresectable Melanomacompleted184
2024-01-25P3ACADIA Pharmaceuticals Inc. ACADNCT04531982 Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of SchizophreniaSchizophreniacompleted454
2024-01-25P3UCB Biopharma SRLNCT04650854 A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia GravisGeneralized Myasthenia Graviscompleted165
2024-01-25P3Takeda TAKNCT04938427 A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut SyndromeLennox Gastaut Syndrome (LGS)completed270
2024-01-25P3BayerNCT05485805 A Study to Learn How Well a Single Dose of the Study Treatment Naproxen Sodium and Caffeine Combined in One Tablet (Fixed-dose Combination) Works to Relieve PaiPostoperative Dental Paincompleted541
2024-01-26P3Hoffmann-La RocheNCT02486718 Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010Non-Small Cell Lung Cancercompleted1280
2024-01-26P1/P2CelgeneNCT03743246 A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cePrecursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkinterminated21
2024-01-26P2Imcyse SANCT04524949 IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study)Diabetes Mellitus, Type 1terminated110
2024-01-26P2Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.NCT04681833 Safety and Efficacy of BARS13 in the ElderlyRespiratory Syncytial Virus Infectionscompleted125
2024-01-26P3Innovent Biologics (Suzhou) Co. Ltd.NCT05606913 A Study of IBI362 in Participants With Type 2 DiabetesType 2 Diabetescompleted731
2024-01-26P2Ocumension Therapeutics (Shanghai) Co., LtdNCT06435182 Study of OT202 in Treating Moderate to Severe Dry EyeDry Eyecompleted213
2024-01-29P1/P2Cardiff Oncology CRDFNCT03829410 Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS MutationMetastatic Colorectal Cancer; KRAS Gene Mutationcompleted68
2024-01-29P3GlaxoSmithKlineNCT04484623 Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple MyelomaMultiple Myelomaactive not recruiting302
2024-01-29P3AbbVie ABBVNCT04542499 Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)Parkinson Diseasecompleted507
2024-01-29P2Incyte Corporation INCYNCT04586244 An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial CarcinomaUrothelial Carcinomaterminated30
2024-01-29P1/P2Adagene Inc ADAGNCT04645069 ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid TumorsAdvanced/Metastatic Solid Tumorscompleted58
2024-01-29P3Hoffmann-La RocheNCT04963270 A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia GravisGeneralized Myasthenia Gravisterminated188
2024-01-29P3AkesoNCT05499390 AK112 in Advanced Non-Small Cell Lung CancerAdvanced Non-small-cell Lung Canceractive not recruiting398
2024-01-29P3BayerNCT05587296 A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy inVasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developinactive not recruiting474
2024-01-29P2argenx ARGXNCT05817669 A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS)Primary Sjögren's Syndromecompleted34
2024-01-30P1/P2Hoffmann-La RocheNCT03671018 A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin LymphomaB-cell Non-Hodgkin Lymphomaactive not recruiting422
2024-01-30P3AlloVirNCT04390113 Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)BK Virus Infection; Hemorrhagic Cystitisterminated97
2024-01-30P1/P2NextCure, Inc. NXTCNCT04875806 A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid TumorsAdvanced or Metastatic Solid Tumors; Ovarian Cancer; Non-small Cell Lung Cancer; Breast Cancerterminated40
2024-01-30P2NeoTX Therapeutics Ltd.NCT04880863 NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLCNon-small Cell Lung Cancercompleted38
2024-01-30P3Novo Nordisk A/S NVONCT04968184 Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)Chronic Kidney Diseasesterminated666
2024-01-30P3Sanotize Research and Development corp.NCT05109611 Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 InfectionSARS-CoV-2 Infectionterminated1389
2024-01-30 est.P2Shanghai Henlius BiotechNCT05127759 The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E MutationMetastatic Colorectal Cancer; mCRCunknown25
2024-01-30P2/P3AlloVirNCT05305040 Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell TransplantAdenovirus Infection; BK Virus Infection; Cytomegalovirus Infections; Epstein-Barr Virus Infections;terminated451
2024-01-30 est.P3Serum Institute of India Pvt. Ltd.NCT05447377 A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy InfantsYellow Feverunknown2216
2024-01-30P3Santen Pharmaceutical Co., Ltd.NCT05503901 A Long Term Study of STN1012600 in Subjects With Open Angle Glaucoma or Ocular HypertensionOpen Angle Glaucoma, Ocular Hypertensioncompleted131
2024-01-30P3Jiangsu Pacific Meinuoke Bio Pharmaceutical Co LtdNCT05679479 Study on the Safety and Efficacy of Meplazumab for Injection in Severe Patients With COVID-19COVID-19completed108
2024-01-30P2Shanghai HEP Pharmaceutical Co., Ltd.NCT05827146 Study of Hepalatide in Chronic Hepatitis D(CHD) PatientsChronic Hepatitis D Infectioncompleted23
2024-01-31 est.P3InnocollNCT03262688 Safety, Tolerability, PK, and Analgesic Effect of INL-001 in Children Following Open Inguinal Hernia RepairInguinal Hernia; Postoperative Painunknown159
2024-01-31P3Jiangsu HengRui Medicine Co., Ltd.NCT03588091 Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast CancerHER2-positive Breast Cancercompleted355
2024-01-31 est.P1/P2Jiangsu vcare pharmaceutical technology co., LTDNCT04614740 The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid TumorsLocally Advanced Solid Tumor; Metastatic Solid Tumorunknown115
2024-01-31P1/P2AlloVirNCT04933968 Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ TransplantRespiratory Tract Viral Infections; Human Metapneumovirus (hMPV) Infection; Parainfluenza (PIV) Infeterminated17
2024-01-31P2Keymed Biosciences Co.LtdNCT05131464 The Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal PolypsChronic Rhinosinusitis With Nasal Polypscompleted46
2024-01-31P3AlloVirNCT05179057 Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic HematopoieticAdenovirus Infectionterminated57
2024-01-31 est.P2CANbridge Life Sciences Ltd.NCT05447195 Phase 2 Study of CAN008 in Subjects With GBMNewly-diagnosed Glioblastomaunknown117
2024-01-31P3Teva Branded Pharmaceutical Products R&D, Inc.NCT05458011 A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With MigraineMigrainecompleted365
2024-01-31P1/P2Nerviano Medical SciencesNCT05630937 Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic TherapyUnresectable Hepatocellular Carcinoma (HCC)terminated31
2024-01-31P3BayerNCT05643573 A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With IrrPrevention of Stroke or Systemic Embolism; Atrial Fibrillationterminated14830
2024-01-31P2Jiangsu HengRui Medicine Co., Ltd.NCT06614153 Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor FluctuationsParkinson's Diseasecompleted61

← 2023-12 | 2024-02 →

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.